Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Deferred Taxes (2020 - 2025)

Historic Deferred Taxes for Autolus Therapeutics (AUTL) over the last 6 years, with Q3 2025 value amounting to -$13000.0.

  • Autolus Therapeutics' Deferred Taxes fell 10773.81% to -$13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 22941.92%. This contributed to the annual value of $185000.0 for FY2024, which is 8123.73% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Deferred Taxes of -$13000.0 as of Q3 2025, which was down 10773.81% from -$384000.0 recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Deferred Taxes high stood at $1.0 million for Q3 2022, and its period low was -$487000.0 during Q1 2025.
  • For the 5-year period, Autolus Therapeutics' Deferred Taxes averaged around $33000.0, with its median value being -$13000.0 (2025).
  • As far as peak fluctuations go, Autolus Therapeutics' Deferred Taxes soared by 33519.31% in 2022, and later tumbled by 41891.89% in 2025.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Deferred Taxes stood at -$276000.0 in 2021, then fell by 15.58% to -$319000.0 in 2022, then skyrocketed by 246.08% to $466000.0 in 2023, then crashed by 130.26% to -$141000.0 in 2024, then surged by 90.78% to -$13000.0 in 2025.
  • Its last three reported values are -$13000.0 in Q3 2025, -$384000.0 for Q2 2025, and -$487000.0 during Q1 2025.